Table 4.
Treatment switching in patients using LAN vs. OCT
| LAN (n = 2327) | OCT (n = 2090) | p value* | |
|---|---|---|---|
| All NETs (N = 4417) | n = 2327 | n = 2090 | |
| Switch to another LA SSA ≤ 3 months after initiation of 1st LA SSA, n (%) | 152 (6.5) | 242 (11.6) | < 0.0001 |
| Switch to another LA SSA between 3 and 12 months after initiation of 1st LA SSA, n (%) | 32 (1.4) | 58 (2.8) | 0.0015 |
| GEP-NETs (N = 2756) | n = 1478 | n = 1278 | |
| Switch to another LA SSA ≤ 3 months after initiation of 1st LA SSA, n (%) | 99 (6.7) | 165 (12.9) | < 0.0001 |
| Switch to another LA SSA between 3 and 12 months after initiation of 1st LA SSA, n (%) | 17 (1.2) | 37 (2.9) | 0.0016 |
| Functioning NETs (N = 629) | n = 357 | n = 272 | |
| Switch to another LA SSA ≤ 3 months after initiation of 1st LA SSA, n (%) | 29 (8.1) | 41 (15.1) | 0.0088 |
| Switch to another LA SSA between 3 and 12 months after initiation of 1st LA SSA, n (%) | 2 (0.5) | 13 (4.8) | 0.0015 |
| Non-functioning NETs (N = 2871) | n = 1434 | n = 1437 | |
| Switch to another LA SSA ≤ 3 months after initiation of 1st LA SSA, n (%) | 100 (7.0) | 150 (10.4) | 0.0013 |
| Switch to another LA SSA between 3 and 12 months after initiation of 1st LA SSA, n (%) | 20 (1.4) | 31 (2.2) | 0.1599 |
GEP-NETs gastroenteropancreatic neuroendocrine tumors, LAN lanreotide autogel, LA SSA long-acting somatostatin analogue, NETs neuroendocrine tumors, OCT octreotide long-acting release
*p values calculated using the chi-squared test